KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Pacific Biosciences Of California (PACB) EBIAT (2016 - 2025)

Pacific Biosciences Of California has reported EBIAT over the past 16 years, most recently at -$40.4 million for Q4 2025.

  • Quarterly results put EBIAT at -$40.4 million for Q4 2025, down 1802.7% from a year ago — trailing twelve months through Dec 2025 was -$546.4 million (down 76.34% YoY), and the annual figure for FY2025 was -$546.4 million, down 76.34%.
  • EBIAT for Q4 2025 was -$40.4 million at Pacific Biosciences Of California, down from -$38.0 million in the prior quarter.
  • Over the last five years, EBIAT for PACB hit a ceiling of $2.4 million in Q4 2024 and a floor of -$426.1 million in Q1 2025.
  • Median EBIAT over the past 5 years was -$71.4 million (2022), compared with a mean of -$88.2 million.
  • Biggest five-year swings in EBIAT: crashed 7028.29% in 2021 and later soared 102.89% in 2024.
  • Pacific Biosciences Of California's EBIAT stood at -$69.3 million in 2021, then dropped by 21.72% to -$84.4 million in 2022, then rose by 2.8% to -$82.0 million in 2023, then soared by 102.89% to $2.4 million in 2024, then crashed by 1802.7% to -$40.4 million in 2025.
  • The last three reported values for EBIAT were -$40.4 million (Q4 2025), -$38.0 million (Q3 2025), and -$41.9 million (Q2 2025) per Business Quant data.